US Stock MarketDetailed Quotes
NKTR Nektar Therapeutics
- 1.3100
- +0.0600+4.80%
Close Sep 13 16:00 ET
- 1.3100
- 0.00000.00%
Post 16:02 ET
241.14MMarket Cap-1455P/E (TTM)
1.3400High1.2400Low748.11KVolume1.2700Open1.2500Pre Close980.71KTurnover0.48%Turnover RatioLossP/E (Static)184.08MShares1.928052wk High3.03P/B202.60MFloat Cap0.412652wk Low--Dividend TTM154.66MShs Float111.3600Historical High--Div YieldTTM8.00%Amplitude0.4126Historical Low1.3100Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Nektar Therapeutics Stock Forum
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
Benzinga· 1 min ago
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
– New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...
No comment yet